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Gene Expression Profiles in Primary Sjögren's Syndrome 
With and Without Systemic Manifestations
Claudio Vitali,1,*  Marzia Dolcino,2 Nicoletta Del Papa,3 Antonina Minniti,3 Francesca Pignataro,3 
Wanda Maglione,3 Claudio Lunardi,2 and Antonio Puccetti4
Objective. To investigate the gene expression profile in patients with Sjögren’s syndrome that is characterized by 
different clinical phenotypes.
Methods. RNA from peripheral blood mononuclear cells was purified in 8 patients with glandular features (GFs) 
and widespread pain (WP) and 11 with extraglandular manifestations (EGMs) and then was analyzed by hybridization 
on a human gene chip exploring more than 40,000 human genes. Differentially expressed genes (DEGs) in the two 
subgroups (ie, those with false discovery rate–corrected P values ≤ 0.01) with respect to 20 healthy controls have 
been submitted to functional classification using a Gene Ontology database and were mapped to define the networks 
of protein to protein interactions (PPIs).
Results. The enriched pathway analyses of DEGs and of the highly interconnected modules identified in the 
PPI networks showed that the pathological processes characterizing the two subgroups were substantially dif-
ferent. The predominant pathways in patients with EGMs are related to T‐ and B-cell activation, Toll‐like receptor, 
interferon signaling, and apoptosis. Conversely, pathological processes related to pain transmission and mod-
ulation are preferentially operative in patients with GFs and WP. These data suggest that a neuroinflammatory 
pathway driven by cytokines and chemokines may play a central role in triggering WP features in this phenotype 
of patients.
Conclusion. The present study supports the hypothesis that different biological pathways are operative in pa-
tients with primary Sjögren’s syndrome with different clinical phenotypes. A better knowledge of these specific pro-
cesses might help in tailoring more effective target therapies.
INTRODUCTION
Primary Sjögren’s syndrome (pSS) is a chronic autoim-
mune disorder whose typical manifestations are oral and ocu-
lar dryness. However, the clinical spectrum of pSS may vary 
from signs and symptoms consequent to the isolated involve-
ment of the salivary and lachrymal glands, or sometimes of 
the other exocrine glands, up to manifestations related to the 
involvement of different organs or systems (1). Extraglandular 
manifestations (EGMs) are present in around 60% of patients 
and are usually distinguished in two types. The first one is 
characterized by lymphocytic infiltrates around the epithelial 
tissues of parenchymal organs, such as the lungs, kidneys, 
and liver. The second type is marked by autoantibodies or 
immune complex deposition in small vessels that may lead to 
the development of porpora, glomerulonephritis and peripheral 
neuropathy (1).
The fact that pSS can present such a wide variability of 
clinical features suggests that different pathogenetic mecha-
nisms may be present in different patients. This hypothesis 
is supported by the finding that a) the number and organi-
zation of mononuclear cells as well as T‐ and B‐cell ratio in 
the infiltrates of target tissues, b) gammaglobulins and anti-
body levels in the serum, and c) cytokine expression in both 
peripheral blood and glands can be different in patients with 
the disease limited to exocrine gland aggression or character-
ized by EGMs (2). Even the impact of fatigue, which represents 
one of the major contributors to the impaired quality of life in 
patients with pSS, is variable in different subsets of patients 
(3). Severe fatigue has been described in approximately one‐
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third of patients and found to be closely associated with wide-
spread pain (WP), anxiety, depression, and impaired sleep 
patterns (3). Unexpectedly, the levels of some proinflammatory 
cytokines that have been found to characterize this disease 
are inversely related to patient‐reported levels of fatigue (4). In 
addition, some data suggest that WP, which is closely related 
to fatigue, is predominant in patients with a disease limited to 
glandular features (GFs) (5).
Because the presence of EGMs, hypergammaglobuline-
mia, cryoglobulinemia, hypocomplementemia, lymphopenia, 
and the germinal center–like organization of mononuclear infil-
trates in the salivary glands are commonly ascribed to B‐cell 
hyperactivity and are also predictors for the development of 
lymphoproliferation (6), targeting B cells has been postulated 
to be an effective therapeutic approach in patients with pSS. 
Therefore, treatment with rituximab, an anti‐CD20 B‐cell sur-
face molecule inducing B‐cell depletion in peripheral blood 
(7), has been tested in patients with pSS. Although prelimi-
nary open label and controlled pilot trials on rituximab therapy 
for pSS have shown improvement in selected subjective and 
objective parameters, two large randomized control trials (8,9) 
failed to reach the primary end points that were mainly rep-
resented by improvement of fatigue and sicca complaints. In 
contrast with these poor results, it has been clearly shown 
that rituximab therapy is effective in reducing the level of some 
serological markers of the disease, such as immunoglobulin 
M–rheumatoid factor, gammaglobulins, and B‐cell number 
also in glandular infiltrates (10). Different hypotheses have 
been raised to explain these negative results. However, it is 
likely that rituximab ineffectiveness could be mainly ascribed 
to the differences in the biological pathways that are operative 
in different subsets of patients with pSS (10). Thus, a better 
knowledge of the genotypic patterns driving the phenotypic 
differentiation of patients may lead to identify the target ther-
apy with the highest probability of success in improving the 
clinical condition and the quality of life of patients with pSS.
With the above considerations in mind, we planned the pres-
ent study to specifically investigate the gene expression profile in 
patients with pSS with different phenotypical characteristics. To 
do so, we decided to select patients situated at the extremities of 
the clinical spectrum of the disease (ie, patients with disease lim-
ited to the involvement of salivary and lachrymal glands and only 
complaining of sicca symptoms and WP) and, on the opposite 
side, patients who, together with sicca manifestations, presented 
with systemic EGMs, such as small joint arthritis, vasculitis, lung 
or kidney involvement, peripheral neuropathy, and lymphoprolifer-
ative lesions.
PATIENTS AND METHODS
Patient selection. Patients classified as having pSS 
according with the American College of Rheumatology (ACR)‐
European League against Rheumatism (EULAR) criteria were 
enrolled in this study (11). We selected patients whose disease 
was limited to glandular involvement and therefore who only 
complain of GFs and WP as well as—on the other extreme—
patients who were characterized by the presence of a wide 
spectrum of EGMs. An accurate workup was completed in all of 
the patients to accurately define their clinical and serological pro-
file. Namely, each EGM was defined according to the European 
SS Disease Activity Index (ESSDAI) nomenclature (12), and the 
cumulative ESSDAI score for systemic activity was calculated. 
Furthermore, the presence of pain and fatigue was scored using 
the Likert scale adopted for these domains in the European SS 
Patient Reported Index (ESSPRI) (13). Furthermore, we classified 
patients as having WP according to ACR definition. Following 
these criteria, WP is defined as the presence of pain in at least 
three sites in the left and right sides of the body, above and 
below the waist, and in the axial skeleton, present for at least 3 
months (14). For each enrolled patient, a clinical examination was 
performed to check the presence and number of fibromyalgia‐ 
associated tender points (14).
Gene expression analysis. An analysis of gene expres-
sion profiles was performed in pSS patients with only GFs as well 
as in pSS patients with EGMs and in 20 age‐ and sex‐matched 
healthy donors.
Blood samples were collected in Vacutainer K2EDTA tubes, 
and peripheral blood mononuclear cells (PBMCs) were isolated 
upon stratification on Lympholyte, a miRNeasy mini kit, following 
the manufacturer’s instructions (Qiagen).
cDNA preparation, sample hybridization, and scanning 
were entrusted to the Cogentech Affymetrix microarray unit 
(Campus IFOM IEO), and the whole procedure was performed 
as described in the Affymetrix protocols (Affymetrix).
Sample hybridization was performed on Human Clariom D 
gene chip (Thermo Fisher Scientific), which interrogates more 
than 40 000 human genes that are approximately represented 
by more than 120 000 probe sets.
Signal intensities of each probe set were analyzed using 
the Transcriptome Analysis Console (TAC) 4.0 software 
(Applied Biosystem). Background subtraction, normalization, 
and log‐transformation of signal intensities were performed 
with The Signal Space Transformation–Robust Multi‐Array 
Average algorithm.
The relative gene expression levels of each transcript were 
validated using the relative one‐way analysis of variance (ANOVA) 
(P ≤ 0.01) with multiple testing correction.
Transcripts that displayed an expression level at least 1.5‐
fold different in the test sample versus control sample (P ≤ 0.01) 
were submitted to functional classification using the Gene Ontol-
ogy (GO) annotations and pathways, and biological process 
enrichments in differentially expressed genes (DEGs) were ana-
lyzed by using Panther expression analysis tools (http://panth 
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erdb.org/) (1). Calculated by the binomial statistical test, P values 
≤ 0.05 were considered as significant enrichment (15).
Validation of the microarray results by real-time 
polymerase chain reaction. The significantly different expres-
sion of genes observed in microarray assay was validated by test-
ing some selected genes with real‐time polymerase chain reaction 
(RT‐PCR) in patients and healthy controls. The method adopted 
for this validation procedure is detailed in the Supplementary 
Methods section (16–18).
Protein-protein interaction, network construction, 
and network clustering. DEGs in test samples versus healthy 
controls that met the above‐mentioned criteria were also mapped 
to the Search Tool for the Retrieval of Interacting Genes (STRING) 
database to analyze protein‐protein interaction (PPI) pairs between 
the protein products of modulated genes, which were validated by 
experimental studies (19). A PPI network was designed, and a 
score of ≥0.7 was selected for each PPI pair.
The STRING database (version 10.5; http://string-db.
org/) covers experimental interactions in more than 1000 fully 
sequenced organisms.
High‐flow areas of the network (modules), characterized by 
the presence of highly connected proteins, were identified by a 
modular analysis employing the CFinder software tool, based on 
the Clique Percolation Method (20). The topological analysis of the 
built networks was performed with the Cytoscape software (21).
Ethical statement. The protocol for the present study was 
prepared in accordance with the guidelines of the 1975 Declara-
tion of Helsinki and the recommendations of local ethical commit-
tee of University of Verona for this kind of study. Written, informed 
consent was obtained from all the enrolled patients and controls.
RESULTS
Patient population. Eight patients with disease expres-
sion limited to GFs and 11 patients characterized by EGMs con-
stituted the two selected subgroups of patients.
The main demographic, clinical, and histologic findings of the 
patients are summarized in Table 1.
For the gene expression analysis, RNAs isolated from the 
PBMCs of four randomly selected patients from each subgroup 
(patients 1, 2, 4, and 8; and 12, 13, 15, and 16) were obtained. 
RNAs from the remaining patients of the two subgroups were 
used for the validation analysis using RT‐PCR.
Gene expression analysis. In comparison with 20 healthy 
controls (volunteers), the DEGs were 2012 and 1679 in patients 
with GFs and EGMs, respectively. The complete lists of DEGs in 
the two subgroups, with the statistical difference compared with 
healthy controls and identification codes, are reported in Supple-
mentary Tables 1 and 2.
The significantly different expression of some genes observed 
in microarray assay was confirmed using the RT‐PCR method. 
The results of this validation test are reported in Supplementary 
Figure 1.
Selectively modulated genes in the two groups were 1021 
and 573 in patients with GFs and EGMs, respectively. The lists of 
these genes are reported in Supplementary Table 3.
When the DEGs in the two subtypes underwent GO func-
tional classification, it was evident that in both groups the large 
majority of DEGs belonged to the same biological processes. 
The modulated genes can be grouped into five main patho-
logical processes: those related to apoptosis, immune and 
inflammatory response, Toll‐like receptor (TLR) signaling and 
type‐I interferon (IFN) signaling. Some less substantial differ-
ences between the subgroups were present in the relative pro-
portions of genes referring to the main functional categories 
(Figure  1). Supplementary Tables 4 and 5 show a selection 
of genes included in the main biological processes in the two 
groups.
However, looking at the genes selectively modulated in the 
two subgroups and at their GO definition, we found that a lim-
ited series of genes involved in the sensory perception pathway 
were exclusively modulated in the group of patients with only 
GFs. Table 2 shows a selection of the above‐mentioned genes. 
Figure 1. Biological processes activated in the two subgroups of patients with primary Sjögren's syndrome, according to Gene Ontology 
functional classifications of differentially expressed genes. The proportions of genes belonging to each biological process are represented in the 
pie charts and slightly differ in the two subgroups.
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Notably, the most strongly overexpressed gene in this list was that 
which codifies for IFN‐γ.
Pathway enrichment analyses showed that almost completely 
different signaling networks were preferentially enriched in patients 
with GFs and WP in comparison with patients with EGMs. In this 
latter subgroup of patients, the B‐cell activation and TLR signaling 
pathways were strongly enriched together with the pathways related 
to 5 hydroxytryptamine (5HT)‐4 receptor signaling and angiotensin 
II (Ang II) receptor signaling (Table 2). Conversely, the most enriched 
pathways in the subgroup of patients with GFs and WP were those 
related to beta‐adrenergic and Notch signaling, 5HT‐1 receptor, 
and corticotropin releasing factor (CRF) receptor signaling (Table 3).
PPI analysis of DEGs allowed the identification of two net-
works that represented all the functional interactions among mod-
ulated genes in the two subgroups of patients. Also, with this kind 
of analysis, relevant differences could be observed in the number 
of genes, composition, density of edges (Figure 2A and B) in the 
PPI network of DEGs in patients with GFs and WP in comparison 
with that derived in patients with EGMs.
The network obtained from PPI analysis of DEGs in 
patients with GFs and WP included 585 codifying genes and 
2166 pairs of interactions (edges) (Figure 2A). This PPI network 
was then submitted to cluster analysis to identify the more 
highly interconnected nodes or modules (M) that are more 
probably involved in determining the typical feature charac-
teristics of different subsets of patients. This modular analysis 
showed the presence of 13 modules that were submitted to 
pathway enrichment analysis. In particular, we observed that 
several genes involved in pain perception and in nociceptive 
signal transduction were present in M0 and M2 (Figure  3A). 
M0 was characterized by the presence of genes codifying 
for endothelin 1 precursor (EDN1), G‐protein subunit γ 2 and 
5 (GNG2; GNG5), lysophosphatidic acid receptor 2 and 5 
(LPAR2; LPAR5), which were also present in M2. In addition, 
genes codifying for C‐C chemokine receptor 5 (CCR5), taste 
Table 2. Overexpressed genes in patients with glandular features and widespread pain, which are members of the “sensory perception” gene 
set, according to the Gene Ontology definition (GO: 0007600)
Gene Symbol Gene Descriptors Functiona Fold Change P value
IFNG Interferon, gamma Proinflammatory cytokine 10.35 0.0009
TRIM26 Tripartite motif containing 26 Transcription factor 2.38 0.0021
TRIM25 Tripartite motif containing 25 Transcription factor 2.18 0.0057
EDN1 Endothelin 1 Inducer of pain perception 3.41 0.009
PML Promyelocytic leukemia protein Regulator of synapsis strength 2.58 0.003
ANPEP Alanyl (membrane) aminopeptidase Inducer of nociceptive pain 9.02 0.0026
TNFRSF1A Tumor necrosis factor receptor superfamily, 
member 1A
Receptor of proinflammatory cytokine 2.09 0.0088
P2RY1 Purinergic receptor P2Y, G-protein coupled, 1 Receptor involved in synaptic transmission 2.1 0.0079
P2RX4 Purinergic receptor P2X, 4 Receptor involved in synaptic transmission 3.52 <0.0001
ADRB1 Adrenoceptor beta 1 Receptor involved in perception of pain 1.86 0.009
GPR75 G protein–coupled receptor 75 Chemokine receptor component 2.13 0.0044
GPR132 G protein–coupled receptor 132 Nociceptive receptor component 2.87 0.0032
GPR137B G protein–coupled receptor 137B Sensory receptor component 3.08 0.0006
GPR37L1 G protein–coupled receptor 37 like 1 Endothelin receptor component 1.98 0.0025
ADCY5 Adenylate cyclase 5 Nociception inducer (via cAMP) 1.89 0.0027
GNG5 Guanine nucleotide binding protein (G protein), Chemokine receptor component γ5 2.2 0.0018
RGS16 Regulator of G-protein signaling 16 Modulator of chemokine receptor 2.78 0.0018
GNG2 Guanine nucleotide binding protein (G protein), Chemokine receptor component γ2 2.03 0.005
LIF Leukemia inhibitory factor Interleukin-6 family cytokine 2.24 0.0046
NFKB1 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1
Transcription factor 4.84 0.0046
FOSL1 FOS-like antigen 1 Postsynaptic stimulation product 3.78 0.0004
CSNK1E casein kinase 1, epsilon Inducer of neuropathic pain 2.24 0.0062
GRINA Glutamate receptor, ionotropic, N-methyl 
D-aspartate-associated protein 1 
Postsynaptic receptor sensible to  
glutamate release
2.21 0.0044
aFunction that the listed genes may have in the context of sensory perception. 
Table 3. Enriched pathways in the two subgroups of patients 
obtained by Panther analysis
Pathways enriched in patients with EGMs P Value
B-cell activation (P00010) 1.49E-02
Toll receptor signaling pathway (P00054) 2.67E-02
5HT-4 type receptor mediated signaling 
pathway (P04376)
3.40E-02
Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin (P05911)
4.54E-02
Pathways enriched in patients with GFs and WP P Value
Beta adrenergic receptor signaling pathway (P04377) 1.42E-02
Notch signaling pathway (P00045) 3.70E-02
5HT1 type receptor mediated signaling pathway 
(P04373)
4.67E-02
Corticotropin releasing factor receptor signaling 
pathway (P04380)
4.89E-02
Abbreviation: EGM, extraglandular manifestation; GF, glandular fea-
ture; WP, widespread pain.
VITALI ET AL 608       |
type 2 receptor 3 (TAS2R3), and adenylate cyclase 5 (ADCY5) 
entered in the composition of this module. Besides the genes 
shared with M0, M2 also included cysteinyl leukotriene recep-
tor 1 (CYSLTR1), P2Y purinoreceptor 1 (P2RY1), and G‐cou-
pled receptor 132 (GPR132).
The enrichment analysis applied to M0 and M2 showed 
that, among the pathways represented in these modules, there 
are those related to G‐proteins, beta adrenergic receptors, 5HT 
receptors, muscarinic receptors, gamma‐aminobutyric acid 
(GABA) receptor, CRF receptor signaling, and to proinflammatory 
cytokine‐chemokine signaling (Figure 3A).
In contrast with M0 and M2, M11 contained genes encod-
ing for anaphase‐promoting complex subunit 5 and 16 (ANAPC5; 
ANAPC16) and for histone H2B type 1‐B proteins (HIST1H2‐BB, 
‐BJ, and ‐BL), CCAT/enhancer‐binding protein beta (CEBPB), 
and nuclear factor NF‐kappa‐B subunit 1 (NFKB1). The anal-
ysis for enriched pathways demonstrates that these genes are 
involved in apoptosis and in immune response, namely in B‐ and 
T‐cell activation and TLR signaling (Figure 3A).
From the PPI analysis of genes modulated only in the sub-
group of patients with EGMs, we obtained a PPI network con-
necting 440 genes (Figure  2B), and from this network, four 
hyperconnected modules were extracted. The pathway enrich-
ment analysis of the four modules showed that no pathways were 
significantly enriched in M0 and M2, whereas in M1 and M3 we 
observed the enrichment of signaling pathways related to apop-
tosis, T‐ and B‐cell activation, TLR and IFN‐γ signaling, as well as 
co‐stimulatory and proinflammatory cytokine signaling (Figure B). 
The complete list of the genes in the modules derived from PPI 
network analysis in the two subgroups of patients and the related 
enriched pathways are reported in Supplementary Tables 6 and 7.
DISCUSSION
We report here the results of gene expression analysis car-
ried out in two strongly differentiated subsets of patients with 
pSS: those with disease limited to GFs, who also complained 
of WP, and those who presented with a variety of EGMs.
DEGs were functionally classified and submitted to a path-
way enrichment analysis to find the most crucial signaling network 
that could be operative in the two subgroups.
The number and type of DEGs were different in the two 
subtypes of patients. Furthermore, patients with disease limited 
to GFs had a higher number of DEGs. This may indicate that 
this kind of patient could have a wider spectrum of pathological 
pathways.
In both subgroups, most of the modulated genes belonged 
to the same few biological processes that are known to be pecu-
liarly activated in pSS (22). However, only in the GFs group were 
genes involved in sensory and pain perception modulated.
Figure 2. Protein‐to‐protein interaction networks of differentially expressed genes in patients with primary Sjögren's syndrome characterized 
by the presence of extraglandular manifestations (EGMs) (A) and with disease expression limited to glandular features (GFs) and widespread 
pain (WP) (B).
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We then performed a cluster analysis of the PPI networks to 
detect areas with the highest levels of interconnections among 
modulated genes (modules) and their associated pathways, 
which could be the drivers of the most important pathological 
mechanisms that are operative in the two subsets of patients.
As in the present study, the few previous studies in this field 
of gene expression analysis in pSS patients was performed using 
PBMCs (23,24). Although these studies were not completely 
comparable because of differences in adopted gene platforms, 
oligonucleotide probe sets, applied analytical software and sta-
tistical analysis, they unanimously demonstrated the central role 
of IFN type I and its induced genes in the pathogenesis of pSS 
(23,24) as well as the association of this gene signature with the 
presence of anti‐Ro/La antibodies (23). In PBMC, pathways also 
related to T‐ and B‐cell activation via their respective receptor 
signaling appeared to be overexpressed (23,24). However, in 
previous studies, in contrast with the present one, no preliminary 
phenotypical characterization and distinction was made in the 
studied cohorts to analyze possible correlations between geno-
typic and phenotypic patterns.
Although some locally activated pathways are certainly 
important to explain the biological processes specifically operative 
Figure 3. Highly interconnected modules obtained by cluster analysis of the protein‐to‐protein interaction networks in patients with glandular 
features and widespread pain (A), and in patients with extraglandular manifestations (B). The enrichment analysis of these modules allows 
recognition of the pathways represented in each module (listed in the lower part of the figure). For the definition and function of the genes 
present in the modules, see the Results section of the text.
(A)
(B)
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in target tissues, it has been largely demonstrated that the anal-
ysis of gene signature in PBMCs can be considered the mirror of 
the main mechanisms that may drive the pathogenesis of some 
systemic autoimmune diseases, such as rheumatoid arthritis and 
systemic lupus (25,26), but also of other organ‐specific immune‐
mediated disorders, such as multiple sclerosis (27). The fact that 
a transcription profile similar to that found in PBMCs has been 
observed in salivary tissue of patients with pSS (24) and, more 
recently, in cells isolated from synovial tissue of patients with pso-
riatic arthritis (28), seems to further support this assumption.
When the analysis of the most enriched pathways was per-
formed in the present study, the results we obtained indicate that 
the predominant signaling networks in the two subsets of patients 
were different. Because the methods to define biological pro-
cesses and enriched pathways in gene expression analysis are 
different, to obtain not completely concordant results from the 
application of these procedures is only apparently contradictory. 
Two sets of genes can be part of the same biological process, 
according to the GO classification system, but can be assigned to 
different signaling pathways when enrichment analysis is applied.
The most enriched pathways that characterized patients with 
GFs and WP are linked to pain perception and modulation pro-
cesses (beta‐adrenergic receptor, CRF, and 5HT receptors signal-
ing) (29–31). The activation in PBMCs of some signaling pathways 
that are commonly believed to be peculiar of neuroendocrine sys-
tem, but not of cells belonging to the immune system, is not sur-
prising. Some studies have shown that a specific gene signature 
is present in PBMCs in non immunoe‐related conditions (32) and 
in neuropsychiatric disorders (33). This is considered the direct 
consequence of the continuous biological cross talk between the 
neuroendocrine system and innate immune cell population that 
induces a reciprocal regulation (34).
Notch signaling is another pathway we found to be 
enriched in patients with GFs and WP. The evolutionary con-
served Notch signaling is a ubiquitous pathway that is involved 
in many biological processes in adulthood. It has been shown 
that Notch signaling is involved in many inflammatory conditions 
(35). Probably via the TLR signal, Notch signaling is activated 
in macrophages and dendritic cells and thus induces these 
cells to proliferate and produce inflammatory cytokines, such as 
TNF‐α and IL‐1β. Thus, Notch signaling plays multiple roles in 
both innate immune response and inflammation. Furthermore, 
Notch signaling has an important role in synaptic plasticity and 
inflammation in the central nervous system (CNS). It seems to 
have an important role in the development of neuropathic pain 
as demonstrated by the fact that the intrathecal administration 
of a Notch signaling inhibitor may prevent the development of 
neuropathic pain (36).
The most enriched pathways in pSS patients with EGMs are 
those related to B‐cell activation and TLR signaling. This confirms 
the previous data indicating that both innate and adaptive immune 
response are enhanced in this subset of patients.
Another pathway that appeared to be enriched in the 
patients with EGMs is that related to angiotensin II. Angiotensin 
II exerts proinflammatory and immune‐mediated actions through 
the interaction with angiotensin II receptor type 1 expressed on 
the surface of macrophages and T cells by inducing the activa-
tion of different kinases, such as mitogen‐activated protein kinase 
(MAPK) and extracellular signal–activated kinase (ERK), which 
are involved in many intracellular transduction signals (37). In this 
pathway, the arrestin system is able to influence various signaling 
systems and modulate chemokine receptor trafficking and sign-
aling as well as apoptosis mechanisms (38). Conversely, the fact 
that the 5HT receptor signaling pathway is also enriched in this 
subgroup suggests that the activation of pain perception path-
ways is an important pathogenetic moment, even in this distinct 
phenotype of patients.
The differences in gene expression in the two subgroups of 
pSS patients, with opposite phenotypic features, appear more 
evident when looking at the PPI network cluster analysis and 
the related enriched pathway analysis. The most interconnected 
genes modulated in patients with EGMs belong to pathways 
involved in innate (apoptosis, TLR and IFN signaling, proinflamma-
tory cytokines) and adaptive (T‐ and B‐cell activation and cooper-
ation) immune responses, which are largely documented in many 
biological studies as playing fundamental roles in pSS (22).
Conversely, by analyzing the PPI network derived from 
patients with GFs and WP, only one module (M11) was composed 
of genes that can be referred to enriched pathways involved in 
innate and adaptive immune responses, whereas M0 and M2 
are dominated by components that belong to pathways that are 
involved in sensory perception and pain modulation mechanisms 
(39). In details, LPAR2, P2RY, beta‐adrenergic receptor, and CRF 
receptor are involved throughout different biological mechanisms 
in central and peripheral pain sensitivity, whereas 5HT receptor 
systems have a double function of descending facilitation or inhi-
bition of pain, and GABA receptor plays an important role in the 
inhibition of ascending painful stimuli (40).
Of particular interest are M0 and M2, in which the enriched 
pathway called “inflammation mediated by chemokines and 
cytokines” is interfaced with genes and their related pathways, 
which are involved in the process of pain perception and mod-
ulation. According to the enriched pathway description, CCR5, 
ADCY5 (present in M0), GNG2, and GNG5 (present in both M0 
and M2) are the modulated genes that are components of this 
pathway. Notably, most of the genes present in M0 and M2 are 
also included among those that, according to the GO definition, 
are members of “sensory perception” gene set (Table 2).
GNG2 and GNG5 are the γ2 and γ5 subunits of specific het-
erodimeric G proteins and thus are essential constituents of some 
subtypes of G protein–coupled receptors (GPCRs). The GPCRs 
are ubiquitously distributed in practically all cells and systems, 
although the large majority of them have been estimated to be 
located in the peripheral nervous system (PNS) and CNS, and 
GENE EXPRESSION IN SJÖGREN'S SYNDROME |      611
drive here important functions in nociceptive signal transmission 
from the periphery and modulation of the upcoming neuropathic 
signals (41,42). The γ subunit, together with the β subunit, are 
constituents of particular GPCR subtypes that are specifically 
linked and activated by all types of chemokines, ie, α (C‐X‐C), 
β (C‐C), γ (CX3C), and δ (XC) chemokines (43,44). The activa-
tion of these receptors is followed by the formation of the sec-
ond messenger, the cyclic adenosine monophosphate (cAMP), 
which is catalyzed by ADCY. cAMP production is only the first 
step of a cascade of events, which includes activation of multiple 
kinases and transcription factors that exert differentiated effects 
on PBMCs, like T‐cell proliferation, migration, aggregation, and 
production of proinflammatory cytokines as well as B cell antigen–
stimulated proliferation (45).
Different chemokine receptors have been identified as prom-
ising therapeutic targets in autoimmune diseases. This approach, 
however, appears to be extremely complicated because of the 
redundancy of chemokines as well as the remarkable complex-
ity and variety of chemokine receptors involved in the recruitment 
of multiple types of immune and inflammatory cells (46). Some 
interesting results regarding the role of chemokines in activating 
the autoimmunity process, and the possibility to consider this 
mechanism as a new potentially effective therapeutic challenge, 
come from animal studies, namely, by the demonstration that the 
inhibition of G protein βγ subunit signaling may abrogate nephritis 
in lupus‐prone mice (47).
On the other hand, there is a large amount of data demon-
strating that the biological sequence represented by chemok-
ine linkage to their specific GPCRs, ADCY catalytic action, 
cAMP intracellular release, and specific kinase activation is an 
essential moment in inducing neuropathic pain and its central 
processing (48,49). A confirmation of this aspect comes from 
the observation that ADCY5 knockout mice have a markedly 
reduced pain response in acute and chronic conditions (50). 
The main actors in the development of neuropathic pain and 
pain sensitization mechanisms are the glia cells, namely, the 
microglia cells resident in PNS and spinal cord (51). Spinal 
microglial cells, but also peripheral nociceptors, and afferent 
postsynaptic neurons express chemokine receptors, and the 
activation of these receptors induces the ADCY‐catalyzed 
cAMP production, the subsequent p38 MAP kinase phospho-
rylation leading to the production of proinflammatory cytokines 
and growth factors (52–54). It has also been shown in many 
experimental studies that T cell–released IFNγ is one of the 
main activators of microglia cells; this step is considered cru-
cial for the induction of neuropathic pain (39). The fact that 
IFNγ is markedly overexpressed in patients with GFs and WP 
may suggest that this mechanism could be important even in 
inducing pain sensitization in this subset of patients.
This complex system can be maintained and even 
enhanced by the ability of activated microglia cells to induce 
a similar activation of astrocytes, which are also important 
actors for the induction of presynaptic/postsynaptic starting of 
excitatory ascending stimuli. Because astrocytes are predom-
inantly located in the brain, it has been postulated that these 
biological processes may also induce central pain sensitization 
(39).
The data obtained in the present study using PBMCs sug-
gest the possibility that specific mediators of inflammatory pro-
cesses may play a role in activating different pathways involved 
in the development of neuropathic pain and central and periph-
eral sensitization. We can hypothesize that the same machinery 
of soluble mediators could become operative in glia and neu-
ronal cells of both the PNS and CNS and thus may trigger the 
development of WP in pSS as well in other autoimmune dis-
ease where similar clinical features have been described (55).
In summary, our data suggest that different pathways driven 
by DEGs are operative in patients with pSS characterized by 
a disease limited to GFs and WP as compared with patients 
phenotypically marked by the presence of EGMs. In the former 
subtype, the phenotypical expression of the disorder could be 
predominantly driven by mechanisms of innate immunity and 
by a cascade of inflammatory cytokines and chemokines. The 
chronic production of these proinflammatory mediators could 
induce pain sensitization and WP.
Conversely, adaptive immune response pathways appear 
to dominate the scene in patients belonging to the other sub-
type of disease that is phenotypically characterized by EGMs. 
Whether these differences may be conditioned by differences 
in genetic susceptibility, as genoma‐wide association studies 
may suggest (56), or modulated by post‐transcriptional epi-
genetic phenomena like DNA methylation defects, histone 
modifications or microRNA‐related activity (57) remains to be 
clarified. Further studies are needed to confirm the present 
preliminary data and to better understand these phenomena. 
More advanced results could both open the possibility to a 
more precise stratification of patients with pSS according to 
the pathological processes activated in different phenotypic 
subsets and offer the opportunity to adopt more precisely tai-
lored therapeutic strategies.
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